TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20447955
Drug: Hyaluronan (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan (sodium hyaluronate; Hyalgan) - 5 intra-articular injections weekly for 5 weeks
Study: 20447955
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) - 5 intra-articular injections weekly for 5 weeks
Study: 17925486
Drug: anti-dsDNA antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-dsDNA antibody
Study: 12834513
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/d or more)
Study: 12834513
Drug: Donepezil (effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (effective dose for at least 9 to 12 months)
Study: 31403816
Drug: Internet-delivered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive-behavioral therapy for CSOs
Study: 30117129
Drug: Eldecalcitol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldecalcitol 0.5 μg
Study: 30117129
Drug: Eldecalcitol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldecalcitol (both doses)
Study: 21120580
Drug: FOLFOX4 (bevacizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 (bevacizumab 5 mg/kg every 2 weeks, FOLFOX4 every 2 weeks)
Study: 21120580
Drug: FFG (bevacizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFG (bevacizumab 5 mg/kg every 2 weeks, FFG weekly for 6 weeks of an 8-week cycle)
Study: 19913311
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng 1 g
Study: 19913311
Drug: Placebo (hop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (hop extract 0.25 g, caramel color 0.05 g, and red ginseng flavor 0.03 g)
Study: 11937315
Drug: Rubitecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubitecan 1.5 mg/m2 after overnight fasting
Study: 11937315
Drug: Rubitecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubitecan 1.5 mg/m2 after a high calorie breakfast
Study: 11937315
Drug: Rubitecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubitecan 1.5 mg/m2/day under fasting conditions for 5 consecutive days per week until disease progression
Study: 10432133
Drug: Soy supplementation
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplementation (60 g of soy powder daily for 3 months)
Study: 1835587
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with buserelin (CAF regimen)
Study: 1835587
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with buserelin (CMF regimen)
Study: 1835587
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with buserelin
Study: 6123719
Drug: Control (Tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Tetracycline ophthalmic ointment)
Study: 31389614
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with adrenaline (5 μg.ml-1)
Study: 27090108
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (1000 mg/day)
Study: 21231862
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 5/30 mg oxycodone HCl/niacin tablets
Study: 21231862
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 7.5/30 mg oxycodone HCl/niacin tablets
Study: 12948274
Drug: Enteric-coated Thai
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated Thai garlic extract tablet (1.12% allicin or 5.6 mg/tablet) once daily for 12 weeks
Study: 1543812
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole in the morning
Study: 1543812
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole in the evening
Study: 27780567
Drug: Experimental ONS
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental ONS (EONS, 20 g protein; 499 IU vitamin D3; 1.5 g CaHMB)
Study: 27780567
Drug: Control ONS
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control ONS (CONS, 14 g protein; 147 IU vitamin D3)
Study: 15500496
Drug: Controlled ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ventilation with muscle relaxants and inhalation anesthesia
Study: 3317346
Drug: Yeast-derived hepatitis
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived hepatitis B vaccine (10, 20, 40 micrograms)
Study: 3317346
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including both yeast-derived and plasma-derived vaccines)
Study: 30786916
Drug: Induction carbon
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction carbon ion radiotherapy (CIRT) boost followed by 60 GyE of proton irradiation with concurrent temozolomide (TMZ) at 75 mg/m2.
Study: 30786916
Drug: CIRT boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIRT boost (dose determined in Phase I of this trial) followed by 60 GyE of proton irradiation with concurrent TMZ.
Study: 30786916
Drug: 60 GyE
Normalized name: DIMETHICONE 0.6 g in 100 mL TOPICAL SHAMPOO [GYEOL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 GyE (2 GyE per fraction) of proton irradiation with concurrent TMZ (control arm).
Study: 27272673
Drug: 6% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyl starch (HES) solution at 24 ml·kg·h
Study: 27272673
Drug: Acetated Ringer's
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer's solution at 24 ml·kg·h
Study: 27272673
Drug: Acetated Ringer's
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer's solution at 2 ml·kg·h
Study: 24565384
Drug: Midazolam 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.025 mg kg(‐1) intravenously
Study: 15738352
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clopidogrel with eptifibatide
Study: 15738352
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clopidogrel without eptifibatide
Study: 15738352
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg clopidogrel without eptifibatide
Study: 7657850
Drug: 200-mg oral
Normalized name: lesinurad
DrugBank: Lesinurad (DB11560)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200-mg oral controlled-release morphine sulfate tablet with naltrexone blockade
Study: 7657850
Drug: two 100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 100-mg MSC tablets
Study: 28703903
Drug: Nemolizumab 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab 0.1 to 3 mg/kg as a single dose once every 4 weeks or 2 mg/kg once every 8 weeks
Study: 25891232
Drug: Daily or
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily or nearly daily drinking
Study: 21251985
Drug: Tanezumab 50μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 50μg/kg administered on Days 1 and 56 with subsequent doses at 8-week intervals (up to a total of eight infusions)
Study: 19117313
Drug: EMLA Cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA Cream (EC)
Study: 19117313
Drug: Placebo (lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lubricant ointment)
Study: 15011220
Drug: Standard advanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard advanced cardiac life support (ACLS) intervention with early empiric administration of bicarbonate (1-mEq/kg dose)
Study: 15011220
Drug: Standard advanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard advanced cardiac life support (ACLS) intervention without early empiric administration of bicarbonate
Study: 11426094
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg intravenously at the time of dural closure
Study: 9437202
Drug: Cholesterol-lowering therapies
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering therapies
Study: 8290902
Drug: Cefpirome 1
Normalized name: cefpirome 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome 1 g bid
Study: 8290902
Drug: Ceftazidime 1
Normalized name: ceftazidime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 1 g bid
Study: 8290902
Drug: Cefpirome 2
Normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome 2 g bid
Study: 8290902
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g tid
Study: 8290902
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g bid
Study: 3326634
Drug: Pindolol, 10
Normalized name: Pindolol, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol, 10 mg twice daily
Study: 28967549
Drug: Methotrexate 15
Normalized name: methotrexate 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 15 mg/wk
Study: 28967549
Drug: Cyclosporine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 2.5 mg/kg/d
Study: 28967549
Drug: Methotrexate 25
Normalized name: methotrexate 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 25 mg/wk (after dose increase)
Study: 28967549
Drug: Cyclosporine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (after dose increase)
Study: 25393089
Drug: Thermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal therapy (sulphurous water insufflation)
Study: 23611571
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg INFS (Treatment A)
Study: 23611571
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg INFS (Treatment B)
Study: 23611571
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg INFS (Treatment C)
Study: 8701045
Drug: artesunate 600
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: artesunate 600 mg followed by mefloquine 500 mg
Study: 8701045
Drug: mefloquine 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: mefloquine 1000 mg
Study: 1735009
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) 37.5 mg/m2 (regimens A and B) or 75 mg/m2 (regimens C and D) + Hexamethylmelamine (HMM) 200 mg/m2 orally daily on days 8‐21
Study: 1735009
Drug: Pyridoxine 300
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine 300 mg/m2 orally on Days 1‐21 (regimens B and D)
Study: 6547795
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (specific type not mentioned)
Study: 30782764
Drug: ToyBox obesity
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: ToyBox obesity prevention intervention; details on dosage and duration not available
Study: 28681171
Drug: R/D/E (ridaforolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: R/D/E (ridaforolimus 10 mg QD 5 ×/week, dalotuzumab 10 mg/kg/week, exemestane 25 mg/day)
Study: 28681171
Drug: R/E (ridaforolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: R/E (ridaforolimus 30 mg QD 5 ×/week, exemestane 25 mg/day)
Study: 15169576
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of r-hFSH and r-hLH (2:1 ratio)
Study: 12177098
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg once monthly
Study: 9875582
Drug: Four-drug oral
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug oral regimen (Rifampin 10 mg/kg daily, Ciprofloxacin 500 mg twice daily, Clofazimine 100 mg every day, Ethambutol 15 mg/kg daily) + Amikacin 10 mg/kg intravenously or intramuscularly 5 days weekly for the first 4 weeks
Study: 9875582
Drug: Four-drug oral
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug oral regimen (Rifampin 10 mg/kg daily, Ciprofloxacin 500 mg twice daily, Clofazimine 100 mg every day, Ethambutol 15 mg/kg daily)
Study: 7597661
Drug: Eformoterol 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eformoterol 24 micrograms twice daily
Study: 6357209
Drug: suprofen 400
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: suprofen 400 mg
Study: 6357209
Drug: ASA 650
Normalized name: ASA 650 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 650 mg + codeine 60 mg
Study: 6357209
Drug: ASA 650
Normalized name: ASA 650 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 650 mg
Study: 20194044
Drug: Co-trimoxazole (CTM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (CTM) 48 mg/kg/day divided into two doses for 1 month
Study: 14685867
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (BC) 60 g.day(‐1)
Study: 9262268
Drug: HCG (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG (5000 IU) after Dexamethasone administration
Study: 28926636
Drug: Per-unit dispensing
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Per-unit dispensing of antibiotics (experimental group)
Study: 28926636
Drug: Traditional pre-packed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional pre-packed boxes of antibiotics (control group)
Study: 27188987
Drug: Low AKG
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low AKG content (LAC, 10 mg AKGs)
Study: 27188987
Drug: High AKG
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High AKG content (HAC, 20 mg AKGs)
Study: 15882526
Drug: dTpa-IPV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTpa-IPV vaccine
Study: 15882526
Drug: dTpa+IPV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTpa+IPV vaccine
Study: 15882526
Drug: Td-IPV vaccine
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td-IPV vaccine
Study: 11211195
Drug: IVIg (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (500 mg/kg/day for 7 days)
Study: 11211195
Drug: Monoclonal anti-CD3
Normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal anti-CD3 (OKT3, 5 mg/day for 14 days)
Study: 7522124
Drug: Combined postoperative
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined postoperative radiation and chemotherapy
Study: 25605189
Drug: Intravenous flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous flurbiprofen axetil and opioids
Study: 25605189
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate sustained-release tablets
Study: 15172863
Drug: 10-mL 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mL 1% lidocaine infusion
Study: 15172863
Drug: 10 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 minutes after lidocaine infusion
Study: 9790153
Drug: Alprazolam 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.125 mg twice a day
Study: 7658064
Drug: Rhesus rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus rotavirus monovalent reassortant vaccine (10^4 pfu)
Study: 7658064
Drug: Tetravalent vaccine
Normalized name: DENGUE TETRAVALENT VACCINE,LIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent vaccine (10^4 pfu)
Study: 2651924
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg nightly
Study: 1132949
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Primperan (20 mg metoclopramide, Lundbeck)
Study: 1132949
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Metopram (20 mg metoclopramide, Leiras)
Study: 22749947
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (4 g over 15 minutes followed by 16 g over 24 hours)
Study: 17317046
Drug: Transdermal E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2/NETA (25 microg E2 and 125 microg NETA applied every 3-4 days)
Study: 17317046
Drug: Oral E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2/NETA (1 mg E2 and 0.5 mg NETA given daily)
Study: 17317046
Drug: Transdermal E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2/NETA
Study: 15284540
Drug: Digital ETCO2/Spo2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital ETCO2/Spo2 monitoring during paramedic rapid sequence intubation (RSI) using midazolam and succinylcholine; rocuronium administered after confirmation of tube position.
Study: 11300330
Drug: Anthracycline-based first-line
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline-based first-line chemotherapy
Study: 10224737
Drug: Behavioral choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral choice treatment (BCT)
Study: 10224737
Drug: Traditional behavioral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional behavioral treatment (TBT)
Study: 1839490
Drug: Teicoplanin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (6 mg/kg q24h i.v. after initial loading at 6 mg/kg q12h for three doses)
Study: 1839490
Drug: Vancomycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (15 mg/kg q12h i.v.)
Study: 6476854
Drug: PUVA-UV-B therapy
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA-UV-B therapy administered twice weekly
Study: 6476854
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of PUVA and UV-B
Study: 31051059
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no HBO2 therapy)
Study: 29314138
Drug: Lower insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower insulin dosages
Study: 26965763
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid fortified milk (FM) providing 400 μg folic acid per day
Study: 23681403
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant chemotherapy (cyclophosphamide-methotrexate-5-fluorouracil or doxorubicin-cyclophosphamide)
Study: 15480981
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice a day plus omeprazole placebo once daily
Study: 15480981
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg twice daily plus omeprazole 20 mg once daily
Study: 10636525
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (2 g over 5 min followed by 16 g over 24 h)
Study: 7924475
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline (loading dose followed by infusion)
Study: 7924475
Drug: Placebo (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equal volume as loading dose and infusion)
Study: 28466660
Drug: Percutaneous polidocanol
Normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous polidocanol injection (PPI)
Study: 23496876
Drug: Lumbar spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar spinal manipulation therapy (SMT)
Study: 21518837
Drug: Intravenous linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous linezolid at 600 mg twice daily
Study: 21518837
Drug: Oral linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral linezolid at 600 mg twice daily
Study: 21518837
Drug: Thrice-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily dosing of intravenous linezolid
Study: 21518837
Drug: Thrice-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily dosing of oral linezolid
Study: 8122021
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose aerosol (Nebuhaler)
Study: 26291338
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive SIJ fusion with triangular titanium implants
Study: 26291338
Drug: Crossover from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover from nonsurgical to surgical treatment
Study: 16439047
Drug: F (226
Approvals — FDA: no, EMA: no, PMDA: no
Description: F (226 microg F/ml as NaF)
Study: 12548082
Drug: simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 80 mg/d
Study: 12548082
Drug: atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 40 mg/d
Study: 10911780
Drug: Mannitol (equiosmolar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (equiosmolar solution)
Study: 10911780
Drug: 0.9 N
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9 N Saline solution
Study: 3891203
Drug: Moxalactam disodium
Normalized name: Moxalactam disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam disodium 2 g every 12 hours
Study: 3891203
Drug: Gentamicin (3-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (3-5 mg/kg/day in three divided doses) and clindamycin phosphate 600 mg every six hours